Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells
- 254 Downloads
Multidrug resistance (MDR) in various kinds of cancers represents a true obstacle which hinders the successes of most of current available chemotherapies. ATP-binding cassette (ABC) trasporter proteins have been shown to contribute to the majority of MDR in various types of malignancies. c-myc has recently been reported to participate, at least partly, in MDR to some types of cancers. This study aimed to test whether c-myc could play a role, solely or with coordination with other ABCs, in the resistance of HepG2 cells to doxorubicin (Dox). MDR has been induced in wild-type HepG2 and has been verified both on gene and protein levels. Various assays including efflux assays as well as siRNA targeting ABCB1 and c-myc have been employed to explore the role of both candidate molecules in MDR in HepG2. Results obtained, with regard to ABCB1 silencing on HepG2/Dox cells, have shown that ABCB1-deficient cells exhibited a significant reduction in ABCC1 expression as compared to ABCB1-sufficient cells. However, these cells did not show a significant reduction in other tested ABCs (ABCC5 and ABCC10) while c-myc silencing had no significant effect on any of the studied ABCs. Moreover, silencing of ABCB1 on HepG2 significantly increased fluorescent calcein retention in HepG2 cells as compared to the control cells while downregulation of c-myc did not have any effect on fluorescent calcein retention. Altogether, this work clearly demonstrates that c-myc has no role in MDR of HepG2 to Dox which has been shown to be ABCB1-mediated in a mechanism which might involve ABCC1.
KeywordsMultidrug resistance HepG2/Dox ABCB1 ABCC1 c-myc
This work was supported by grants from the Science and Technology Development Fund (STDF), Egypt, Basic and Applied Research Grant (Project ID 4361). We thank Ghada H. El-sayed, Heba K. Nabih, Eman M. Abdel Motaleb, and Alaa Shahin for technical help.
- 4.Kim D, Kim M, Kim H, Leea J, Baea J, Kim D, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta. 1812;2011:796–805.Google Scholar
- 13.Tiwari AK, Sodani K, Chen ZS. Current advances in modulation of ABC transporter-mediated multidrug resistance in cancer. Int J Toxicol Pharmcol Res. 2009;1:1–6.Google Scholar
- 23.Borel F, Logtenstein R, Koornneef A, Maczuga P, Ritsema T, Petry H, et al. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAi Gene Silenc. 2011;7:434–42.Google Scholar
- 24.Qiu J, Zhang Y, Li Y, Zhao Y, Zhang W, Jiang Q, et al. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotargets. 2015;6(17):15495–509.Google Scholar